Myomo to Participate in Two Investor Conferences in September
BOSTON (September 5, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that management will be participating in two investor conferences during the month of September. Read more.
Myomo Reports Second Quarter 2024 Financial Results
Record revenue of $7.5 million Record 213 MyoPro® authorizations and orders Record 550 additions to the pipeline, with 1,179 patients in the pipeline at quarter-end BOSTON (August 6, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and […]
Myomo to Report Second Quarter Financial Results on August 6, 2024
BOSTON (July 30, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the second quarter ended June 30, 2024 on August 6, 2024. (Read more)
Myomo Reports Preliminary Second Quarter 2024 Revenues and Operating Metrics
Expects record quarterly revenues of $7.2 million to $7.4 million, an increase of 92% to 97% sequentially Generates record pipeline additions, and authorizations and orders BOSTON (July 8, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and […]
Myomo to Present at Sidoti Virtual Conference
BOSTON (June 5, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, chairman and chief executive officer and David Henry, chief financial officer, will present and host one-on-one meetings with […]
Myomo Reports First Quarter 2024 Financial Results
Record 275 patients in backlog, includes 180 authorizations and orders in Q1, up 48% over the prior year Record 493 MyoPro candidates added to the pipeline in Q1 Revenue of $3.8 million, up 9% over the prior year Conference call begins at 4:30 p.m. Eastern time today BOSTON (May 8, 2024) – Myomo, Inc. (NYSE […]
Myomo Announces First Lump Sum Reimbursements for MyoPros Delivered to Medicare Part B Beneficiaries Under New CMS Fees
Claims Remitted for Payment by All Four Billing Regions Orthotics and Prosthetics Providers Beginning to Receive Reimbursement at Published Rates BOSTON (May 6, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that […]
Myomo to Report First Quarter Financial Results on May 8, 2024
BOSTON (May 1, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the first quarter ended March 31, 2024 on May 8, 2024. Read more.
Myomo Appoints Heather Getz to its Board of Directors
BOSTON (March 28, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Heather Getz as a Class II director and chair of its audit committee effective March 26, 2024, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has seven directors.
Myomo Reports Fourth Quarter and Full Year 2023 Financial Results
Q4 total revenue of $4.8 million, up 18% over the prior year Addition of Medicare Part B patients to backlog results in record 183 MyoPro orders and insurance authorizations received in Q4, up 87% over the prior year Record backlog of 230 patients as of December 31, 2023 Introduces 2024 first quarter and full year […]